CD274 and non-small cell lung carcinoma: Multivariate analyses revealed that the GPS and BMI were independently associated with OS, suggesting that the GPS and BMI may be used to predict the OS among patients with high PD‐L1 expression undergoing first‐line pembrolizumab monotherapy for NSCLC.